Replies to post #74896 on Biotech Values

[DewDiligence]

Re: Role of interferon in HCV combination therapy

It's MoA and pre-clinical data, and, per your own sentiments, thus somewhat suspect.

Once again, I respectfully disagree. The idea laid out in my prior post is considerably more than mere MoA handwaving; I can cite the past 20 years of clinical data in HIV as indicative of the direction in which HCV is heading.

Do you think GILD’s chief scientific officer has some credibility in this arena? His view is essentially the same as mine. I invite you to listen to some of GILD’s recent CC’s.

[tony111]

Clark do you think Ribavirin itself is sufficient to control the relapse rate or does it only do its magic when it is combined with IFN.